New Buy Alert! Rare Disease Developer Set for an Upcoming FDA Decision
With strong efficacy and safety data, this company is a strong contender for FDA approval next month. With its technology, it would be the only oral drug in a market that generates about $2 billion in annual sales. That's a huge competitive advantage…
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Profit Alert
The FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.